Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer (Q38847914)

7 September 2017

title

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer (English)

1 reference

7 September 2017

C Hardin

1

1 reference

7 September 2017

E Shum

2

1 reference

7 September 2017

A P Singh

3

1 reference

7 September 2017

R Perez-Soler

4

1 reference

7 September 2017

H Cheng

5

1 reference

7 September 2017

language of work or name

English

0 references

publication date

7 April 2017

1 reference

Expert Opinion on Pharmacotherapy

7 September 2017

published in

1 reference

7 September 2017

volume

18

1 reference

7 September 2017

issue

7

1 reference

7 September 2017

page(s)

701-716

1 reference

Comprehensive molecular profiling of lung adenocarcinoma

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Taxol: an antimitotic agent with a new mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Cell death by mitotic catastrophe: a molecular definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Targeting microtubules for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Metronomics: towards personalized chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

New drugs in non-small cell lung cancer. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Eribulin: a novel cytotoxic chemotherapy agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Targeted anti-mitotic therapies: can we improve on tubulin agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Tubulin inhibitors in non-small cell lung cancer: looking back and forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

New Colchicine-Derived Triazoles and Their Influence on Cytotoxicity and Microtubule Morphology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Unusual tubulin-clustering ability of specifically c7-modified colchicine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A Novel Resveratrol Based Tubulin Inhibitor Induces Mitotic Arrest and Activates Apoptosis in Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of α-Tubulin and Inhibition of Microtubule Formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

An immunosurveillance mechanism controls cancer cell ploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Immunogenic anti-cancer chemotherapy as an emerging concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

MEK inhibition in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

New insights in beta-tubulin sequence analysis in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Do beta-tubulin mutations have a role in resistance to chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

New insights into mechanisms of resistance to microtubule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Microtubule-Binding Proteins as Promising Biomarkers of Paclitaxel Sensitivity in Cancer Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

MicroRNAs: novel mediators of resistance to microtubule-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1316374

10.1080/14656566.2017.1316374

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference